@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAQfimzcuO2ykczO02USbQrPWiygzYZWpE-ojuEE2HGbI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAQfimzcuO2ykczO02USbQrPWiygzYZWpE-ojuEE2HGbI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 occursIn: do:9351 , obo:CL_0000066 , obo:UBERON_0001977 , species:9606 ;
    rdf:object go:0006094 ;
    rdf:predicate belv:decreases ;
    rdf:subject chebi:6801 ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(CHEBI:metformin) -| bp(GOBP:gluconeogenesis)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_3 ;
    pav:version "20131211" .
  sub:_2 prov:value "metformin is as an activator of the AmPK–lKb1 pathway5,126. In liver, this results in inhibition of gluconeogenesis and hepatic glucose output, which in turn reduces circulating glucose level, resulting in a secondary decrease in insulin level. In transformed epithelial cells, metformin, similarly to other AmPK activators, inhibits rather than increases insulin-stimulated proliferation6,7." ;
    prov:wasQuotedFrom pubmed:19029956 .
  sub:_3 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:19029956 ;
    prov:wasDerivedFrom beldoc: , sub:_2 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:33:29.449+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}